The Current State of Stem Cell Therapeutics: Canadian Approaches in the International Context

Canadian Journal of Cardiology

Volumn 30, Issue 11, 2014, Pages 1361-1369

  Noiseux, Nicolas ^a   Marquis Gravel, Guillaume ^a   Mansour, Samer ^a   Shahzad, Uswa ^b   Stewart, Duncan J ^c   Yau, Terrence M ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; CANADIAN; CHRONIC DISEASE; HUMAN; ISCHEMIC CARDIOMYOPATHY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL THERAPY; CANADA; CELL DIFFERENTIATION; CYTOLOGY; HEART DISEASES; HEART MUSCLE CELL; PROCEDURES;

ANIMALS; CANADA; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; HEART DISEASES; HUMANS; MYOCYTES, CARDIAC; STEM CELL TRANSPLANTATION;

EID: 84908496146     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.04.031     Document Type: Review

References (63)

1. Malliaras K., Marban E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull 2011, 98:161-185.
2. Dowell J.D., Rubart M., Pasumarthi K.B., Soonpaa M.H., Field L.J. Myocyte and myogenic stem cell transplantation in the heart. Cardiovasc Res 2003, 58:336-350.
3. Hassink R.J., Brutel de la Riviere A., Mummery C.L., Doevendans P.A. Transplantation of cells for cardiac repair. JAm Coll Cardiol 2003, 41:711-717.
4. Jackson K.A., Majka S.M., Wulf G.G., Goodell M.A. Stem cells: a minireview. JCell Biochem Suppl 2002, 38:1-6.
5. Watanabe E., Smith D.M., Delcarpio J.B., et al. Cardiomyocyte transplantation in a porcine myocardial infarction model. Cell Transplant 1998, 7:239-246.
6. Min J.Y., Yang Y., Sullivan M.F., et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. JThorac Cardiovasc Surg 2003, 125:361-369.
7. Chugh A.R., Beache G.M., Loughran J.H., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012, 126:S54-64.
8. Murry C.E., Wiseman R.W., Schwartz S.M., Hauschka S.D. Skeletal myoblast transplantation for repair of myocardial necrosis. JClin Invest 1996, 98:2512-2523.
9. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001, 7:430-436.
10. Jain M., Pfister O., Hajjar R.J., Liao R. Mesenchymal stem cells in the infarcted heart. Coron Artery Dis 2005, 16:93-97.
11. Strauer B.E., Brehm M., Zeus T., et al. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction [in German]. Dtsch Med Wochenschr 2001, 126:932-938.
12. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106:1913-1918.
13. Hendrikx M., Hensen K., Clijsters C., et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplan- tation: results from a randomized controlled clinical trial. Circulation 2006, 114:I101-I107.
14. Schächinger V., Erbs S., Elsässer A., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. NEngl J Med 2006, 355:1210-1221.
15. Lunde K., Solheim S., Aakhus S., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. NEngl J Med 2006, 355:1199-1209.
16. Traverse J.H., Henry T.D., Ellis S.G., et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011, 306:2110-2119.
17. Mozid A.M., Jones D., Arnous S., et al. The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease. Stem Cells Dev 2013, 22:216-223.
18. Kang H.J., Lee H.Y., Na S.H., et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006, 114:I145-I151.
19. Muller-Ehmsen J., Tossios P., Schmidt M., et al. Transmurality of scar influences the effect of a hybrid-intervention with autologous bone marrow cell injection and aortocoronary bypass surgery (MNC/CABG) in patients after myocardial infarction. Int J Cardiol 2012, 156:303-308.
20. Seeger F., Rasper T., Fischer A., et al. Heparin disrupts the CXCR4/SDF-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair. Circ Res 2012, 111:854-862.
21. Meluzin J., Mayer J., Groch L., et al. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J 2006, 152:975.e9-975.e15.
22. Heldman A.W., DiFede D.L., Fishman J.E., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 2014, 311:62-73.
23. Brunskill S.J., Hyde C.J., Doree C.J., Watt S.M., Martin-Rendon E. Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. Eur J Heart Fail 2009, 11:887-896.
24. Assmus B., Walter D.H., Seeger F.H., et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013, 309:1622-1631.
25. Jeevanantham V., Butler M., Saad A., et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 2012, 126:551-568.
26. Surder D., Manka R., Lo Cicero V., et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation 2013, 127:1968-1979.
27. Pokushalov E., Romanov A., Chernyavsky A., et al. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized stud. JCardiovasc Transl Res 2010, 3:160-168.
28. Rende X, Song D, Yichao Z, Jun P, Ben H. Autologous transplantation of bone-marrow/blood-derived cells for chronic ischemic heart disease: a systematic review and meta-analysis [e-pub ahead of print]. Can J Cardiol doi: , accessed January 27, 2014. doi:10.1016/j.cjca.2014.01.013.
29. Bartunek J., Behfar A., Dolatabadi D., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. JAm Coll Cardiol 2013, 61:2329-2338.
30. Perin E.C., Silva G.V., Henry T.D., et al. Arandomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011, 161:1078-1087.e3.
31. Perin E.C., Willerson J.T., Pepine C.J., et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012, 307:1717-1726.
32. Marquis-Gravel G, Stevens LM, Mansour S, Avram RC, Noiseux N. Stem cell therapy for the treatment of non-ischemic cardiomyopathy: a systematic review of the literature and meta-analysis of randomized controlled trials [e-pub ahead of print]. Can J Cardiol, DOI: , accessed September 5, 2014. doi:10.1016/j.cjca.2014.03.026.
33. Chen S.L., Fang W.W., Ye F., et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004, 94:92-95.
34. Mansour S., Roy D.C., Bouchard V., et al. One-year safety analysis of the COMPARE-AMI trial: comparison of intracoronary injection of CD133 bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction. Bone Marrow Res 2011, 2011:385124.
35. Forcillo J., Stevens L.M., Mansour S., et al. Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial. Can J Cardiol 2013, 29:441-447.
36. Bolli R., Chugh A.R., D'Amario D., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase I trial. Lancet 2011, 378:1847-1857.
37. Hare J.M., Fishman J.E., Gerstenblith G., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
38. Quirici N., Soligo D., Caneva L., et al. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001, 115:186-194.
39. Stamm C., Westphal B., Kleine H.D., et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361:45-46.
40. Agbulut O., Vandervelde S., Al Attar N., et al. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. JAm Coll Cardiol 2004, 44:458-463.
41. Colombo A., Castellani M., Piccaluga E., et al. Myocardial blood flow and infarct scar size after CR133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial. JCardiovasc Med 2011, 12:239-248.
42. Quyyumi A., Waller E.K., Murrow J., et al. CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011, 161:98-105.
43. Bartunek J., Vanderheyden M., Vandekerckhove B., et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005, 112:I178-I183.
44. Mansour S., Vanderheyden M., De Bruyne B., et al. Intracoronary delivery of hematopoietic bone marrow stem cells and luminal loss of the infarct-related artery in patients with recent myocardial infarction. JAm Coll Cardiol 2006, 47:1727-1730.
45. Vanderheyden M., Vercauteren S., Mansour S., et al. Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction. Cell Transplant 2007, 16:919-925.
46. Mansour S., Roy D.C., Bouchard V., et al. COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design. JCardiovasc Trans Res 2010, 3:153-159.
47. Stamm C., Kleine H.D., Choi Y.H., et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. JThorac Cardiovasc Surg 2007, 133:717-725.
48. Patel A., Geffner L., Vina R.F., et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. JThorac Cardiovasc Surg 2005, 130:1631-1638.
49. Nasseri B.A., Ebell W., Dandel M., et al. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial. Eur Heart J 2014, doi:10.1093/eurheartj/ehu007.
50. Donndorf P., Kaminski A., Tiedemann G., Kundt G., Steinhoff G. Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter trial: study protocol for a randomized controlled trial. Trials 2012, 13:99.
51. Taljaard M., Ward M.R., Kutryk M.J., et al. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J 2010, 159:354-360.
52. Schulman I.H., Hare J.M. Key developments in stem cell therapy in cardiology. Regen Med 2012, 7:17-24.
53. Haider H., Ashraf M. Preconditioning and stem cell survival. JCardiovasc Transl Res 2010, 3:89-102.
54. Noiseux N., Gnecchi M., Lopez-Ilasaca M., et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006, 14:840-850.
55. Fischer K.M., Cottage C.T., Wu W., et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 2009, 120:2077-2087.
56. Noiseux N., Borie M., Desnoyers A., et al. Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology 2012, 153:5361-5372.
57. Psaltis P.J., Zannettino A.C., Worthley S.G., Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008, 26:2201-2210.
58. Der Sarkissian S., Borie M., Hamet P., Noiseux N. Pre-conditioning of stem cell with celastrol to enhance their therapeutical potential (abstract). Circulation 2011, 124:A14198.
59. Allen K.B., Kelly J., Borkon A.M., et al. Transmyocardial laser revascularization: from randomized trials to clinical practice. A review of techniques, evidence-based outcomes, and future directions. Anesthesiol Clin 2008, 26:501-519.
60. Atluri P., Panlilio C.M., Liao G.P., et al. Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function. JThorac Cardiovasc Surg 2008, 135:283-291. 91.e1[discussion: 91].
61. Spiegelstein D., Kim C., Zhang Y., et al. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. Am J Physiol Heart Circ Physiol 2007, 293:H3311-H3316.
62. Shahzad U., Li G., Zhang Y., Yau T.M. Transmyocardial revascularization induces mesenchymal stem cell engraftment in infarcted hearts. Ann Thorac Surg 2012, 94:556-562.
63. Rosenzweig A. Cardiac cell therapy-mixed results from mixed cells. NEngl J Med 2006, 355:1274-1277.